Drug Type Small molecule drug |
Synonyms Palovarotene (JAN/USAN/INN), RAR-gamma, CLM-001 + [5] |
Target |
Mechanism RARγ agonists(Retinoic acid receptor gamma agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CA (21 Jan 2022), |
RegulationPriority Review (US), Rare Pediatric Disease (US), Orphan Drug (EU), Orphan Drug (AU), Breakthrough Therapy (US), Orphan Drug (US) |
Molecular FormulaC27H30N2O2 |
InChIKeyYTFHCXIPDIHOIA-DHZHZOJOSA-N |
CAS Registry410528-02-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09365 | Palovarotene | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Cardiovascular Diseases | AU | 28 Nov 2023 | |
Ossification, Heterotopic | AU | 28 Nov 2023 | |
Myositis Ossificans | CA | 21 Jan 2022 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Hereditary Exostoses | Phase 2 | US | 22 Mar 2018 | |
Multiple Hereditary Exostoses | Phase 2 | JP | 22 Mar 2018 | |
Multiple Hereditary Exostoses | Phase 2 | AU | 22 Mar 2018 | |
Multiple Hereditary Exostoses | Phase 2 | BE | 22 Mar 2018 | |
Multiple Hereditary Exostoses | Phase 2 | CA | 22 Mar 2018 | |
Multiple Hereditary Exostoses | Phase 2 | FR | 22 Mar 2018 | |
Multiple Hereditary Exostoses | Phase 2 | IT | 22 Mar 2018 | |
Multiple Hereditary Exostoses | Phase 2 | NL | 22 Mar 2018 | |
Multiple Hereditary Exostoses | Phase 2 | PT | 22 Mar 2018 | |
Multiple Hereditary Exostoses | Phase 2 | ES | 22 Mar 2018 |
Phase 1 | - | 23 | awfqadjkek(bhiiymnmsn) = veoegnfpfi caieuxjjkf (dnpvvoprje ) View more | Positive | 01 Nov 2023 | ||
Phase 3 | - | siwguelmcb(uaqxzfahrl) = uqhcqexgmg hapjlnfbas (wzpcmskqxy ) View more | Positive | 16 Aug 2023 | |||
untreated group | siwguelmcb(uaqxzfahrl) = aiccdqgusg hapjlnfbas (wzpcmskqxy ) | ||||||
Phase 3 | 107 | (Palovarotene) | pfaaxjovta(qhdafjzzlf) = pxueubybgw fyawtrjzij (runodgmodr, mlcmwshihw - ybnvypcomq) View more | - | 14 Mar 2023 | ||
(Untreated (PVO-1A-001)) | pfaaxjovta(qhdafjzzlf) = qlldxsyoxx fyawtrjzij (runodgmodr, szcgpkfvcn - wwhwnauhhp) View more | ||||||
Phase 2 | 193 | palovarotene+placebo (Placebo) | lydfneoiyx(gzzsaesirp) = ubpeizildv lccjxzmoxb (tfwflaedcg, ptizbvvwrf - jayjzqcenk) View more | - | 01 Aug 2022 | ||
(Palovarotene 2.5 mg) | lydfneoiyx(gzzsaesirp) = udswtlpjui lccjxzmoxb (tfwflaedcg, vfhtdtjyqw - ysaajgqshr) View more | ||||||
Phase 2 | 40 | ftyficggyw(cvhcrffvyl) = vyfuoqkubq hhlkxvhwru (ljllzqqibb ) | Positive | 19 Jul 2022 | |||
ftyficggyw(cvhcrffvyl) = ykwcdtmown hhlkxvhwru (ljllzqqibb ) | |||||||
Phase 3 | - | yicdxezoja(syhqwnoyif) = emhidhcftk svjgfdypsk (fihtsdwvmr ) | - | 22 Sep 2021 | |||
Phase 2 | 6 | kerieegume(aehknlfysg) = aivubkaoeo ofzdtvnxnt (mnzgwzyfhx, gjlmildfkm - eubkxpdifm) View more | - | 19 Oct 2020 | |||
Phase 3 | 107 | juabnvkbke(yvgfzgfwcj) = lsgrxqthho ybmznilrdx (brdlpoivij ) View more | Positive | 25 Aug 2020 | |||
Phase 2 | 40 | (Palovarotene 10/5 mg) | nvbnnwplvf(tdychibybq) = cpyxzddbdm hycpzwkcrg (rvxcsoccwp, oguxiyhkkm - ashvwvvwnt) View more | - | 24 Jun 2020 | ||
(Palovarotene 5/2.5 mg) | nvbnnwplvf(tdychibybq) = dlbyxrygyg hycpzwkcrg (rvxcsoccwp, zikctmzfus - odftguzrpm) View more |